Eric P. Grewal, MD, MMSc
|
Investigator, Instructor (M) Neurosurgery, Mass General Research Institute |
| BA - Immunology, UC Berkeley |
| MD - Doctor of Medicine, Mayo Clinic |
| MMSc - Immunology, Harvard Medical School |
Research Interests
Research Narrative
Dr. Grewal is an immunologist and cell therapy physician with expertise in the discovery, translation, and clinical evaluation of novel immunotherapies for cancer. He is currently the inaugural A Shot for Life Endowed Scholar in Brain Tumor Immunotherapy at Massachusetts General Hospital, where he works under the leadership of Dr. Bryan Choi and Dr. William Curry to discover and develop novel treatments for brain tumors. He also serves as Translational Director for brain tumor cell therapy initiatives, leading regulatory submissions, GMP manufacturing efforts, and clinical trial protocol development to enable promising cell therapy candidates to be tested among patients with unmet medical needs.
As a clinical investigator, he has played key roles in multiple high-profile phase I & II clinical trials of immunotherapies such as tumor vaccines, checkpoint inhibitors, and CAR T cells for patients with solid tumors. As a basic scientist, he has also investigated novel tumor vaccine formulations, next-generation CAR T & CAR-NK cells, innate immune agonists, bispecific antibodies, and TCR-based therapies in preclinical mouse models and human cells.
With formal training in clinical pathology, Dr. Grewal possesses particular strengths in the translational medicine realm, having lead complex analyses of plasma, tissue, and immunologic biomarkers using both traditional platforms as well as advanced bioinformatics technologies such as scRNA-seq, mass cytometry, AI/machine learning-based platforms, and multiplexed spatial imaging. As an Instructor of Neurosurgery at Harvard Medical School, Dr. Grewal also enjoys teaching and mentoring students, clinical trainees, postdoctoral fellows, and staff researchers.
A native of the West Coast, Dr. Grewal studied at UC Berkeley, Harvard Medical School, and Mayo Clinic before completing his medical residency at Massachusetts General Hospital, where he also pursued advanced training in Cellular Immunotherapy at the Ragon Institute of Mass General, MIT, and Harvard. He has previously held research appointments at the Institute for Systems Biology, Aduro Biotech (now a subsidiary of Novartis), Mayo Clinic Cancer Center, and Dana-Farber Cancer Institute. Dr. Grewal maintains active medical licensure and is certified by the American Board of Pathology.